Advertisement
Screener

Tempest Therapeutics, Inc. (TPST) Restructuring Charges

2.8 / 5 stars · 68/120 Roast Me

Tempest Therapeutics, Inc. Restructuring Charges

Tempest Therapeutics, Inc. (TPST) reported Restructuring Charges of $53.00 thousand for the 3-month period ending 2018-09-30, per its 10-Q filed 2018-11-09.

Discontinued › Expense Statement › Operating Expenses

us-gaap:RestructuringCharges · last filed 2018-11-09

  • Tempest Therapeutics, Inc. restructuring charges for the quarter ending 2018-09-30 was $53.00K, a 85.32% decline year-over-year.
  • Tempest Therapeutics, Inc. restructuring charges for the quarter ending 2018-06-30 was $2.89M, a 45.18% increase year-over-year.
  • Tempest Therapeutics, Inc. restructuring charges for the quarter ending 2018-03-31 was $692.00K, a 53.49% decline year-over-year.
  • Tempest Therapeutics, Inc. restructuring charges for the quarter ending 2017-12-31 was $188.00K, a 96.52% decline year-over-year.
  • Tempest Therapeutics, Inc. restructuring charges for fiscal 2017 was $4.03M, a 25.37% decline from fiscal 2016.
  • Tempest Therapeutics, Inc. restructuring charges for fiscal 2016 was $5.40M.
  • Tempest Therapeutics, Inc. restructuring charges for fiscal 2015 was $0.00.
  • Tempest Therapeutics, Inc. restructuring charges for fiscal 2014 was $0.00.
Period endRestructuring Charges 3 monthRestructuring Charges 6 monthRestructuring Charges 9 monthRestructuring Charges 12 month
2018-09-30$53.00K
10-Q · filed 2018-11-09
$2.94M
derived: sum of 2 quarters · filed 2018-11-09
$3.64M
10-Q · filed 2018-11-09
$3.83M
derived: sum of 4 quarters · filed 2018-11-09
2018-06-30$2.89M
10-Q · filed 2018-08-09
$3.58M
10-Q · filed 2018-08-09
$3.77M
derived: sum of 3 quarters · filed 2018-08-09
$4.13M
derived: sum of 4 quarters · filed 2018-11-09
2018-03-31$692.00K
10-Q · filed 2018-05-03
$880.00K
derived: sum of 2 quarters · filed 2018-05-03
$1.24M
derived: sum of 3 quarters · filed 2018-11-09
$3.23M
derived: sum of 4 quarters · filed 2018-11-09
2017-12-31$188.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15
$549.00K
derived: sum of 2 quarters · filed 2018-11-09
$2.54M
derived: sum of 3 quarters · filed 2018-11-09
$4.03M
10-K · filed 2018-03-15
2017-09-30$361.00K
10-Q · filed 2018-11-09
$2.35M
derived: sum of 2 quarters · filed 2018-11-09
$3.84M
10-Q · filed 2018-11-09
$9.24M
derived: sum of 4 quarters · filed 2018-11-09
2017-06-30$1.99M
10-Q · filed 2018-08-09
$3.48M
10-Q · filed 2018-08-09
$8.88M
derived: sum of 3 quarters · filed 2018-08-09
$8.88M
derived: sum of 4 quarters · filed 2018-08-09
2017-03-31$1.49M
10-Q · filed 2018-05-03
$6.89M
derived: sum of 2 quarters · filed 2018-05-03
$6.89M
derived: sum of 3 quarters · filed 2018-05-03
$6.89M
derived: sum of 4 quarters · filed 2018-05-03
2016-12-31$5.40M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15
$5.40M
derived: sum of 2 quarters · filed 2018-03-15
$5.40M
derived: sum of 3 quarters · filed 2018-03-15
$5.40M
10-K · filed 2018-03-15
2016-09-30$0.00
10-Q · filed 2017-11-02
$0.00
derived: sum of 2 quarters · filed 2017-11-02
$0.00
10-Q · filed 2017-11-02
2016-06-30$0.00
10-Q · filed 2017-08-03
$0.00
10-Q · filed 2017-08-03
2016-03-31$0.00
10-Q · filed 2017-05-09
2015-12-31$0.00
10-K · filed 2018-03-15
2014-12-31$0.00
10-K · filed 2017-03-02

Similar stocks

Stock NameCountryMarket CapPE Ratio
Aspire Biopharma Holdings, Inc. (ASBP)United States$0.012B-0.60
AEON Biopharma, Inc. (AEON)United States$0.013B-0.36
BIOVIE INC. (BIVI)United States$0.012B
MUSTANG BIO, INC. (MBIO)United States$0.013B
Vistagen Therapeutics, Inc. (VTGN)United States$0.013B-0.14
ADIAL PHARMACEUTICALS, INC. (ADIL)United States$0.012B
Phio Pharmaceuticals Corp. (PHIO)United States$0.012B-0.92
Scienture Holdings, Inc. (SCNX)United States$0.012B-0.38
LISATA THERAPEUTICS, INC. (LSTA)United States$0.014B-2.13
KIORA PHARMACEUTICALS INC (KPRX)United States$0.012B